What's in a Label? Radioimmunotherapy for metastatic prostate cancer

Charles B Simone 2nd; Stephen M Hahn

doi:10.1158/1078-0432.CCR-13-1540

What's in a Label? Radioimmunotherapy for metastatic prostate cancer

Clin Cancer Res. 2013 Sep 15;19(18):4908-10. doi: 10.1158/1078-0432.CCR-13-1540. Epub 2013 Aug 7.

Authors

Charles B Simone 2nd¹, Stephen M Hahn

Affiliation

¹ Authors' Affiliation: Department of Radiation Oncology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania.

PMID: 23926229
DOI: 10.1158/1078-0432.CCR-13-1540

Abstract

Prostate cancer has a highly tumor-restricted prostate-specific membrane antigen (PSMA) and may be the ideal solid-organ malignancy for treatment with radioimmunotherapy. Encouraging results using lutetium-177-labeled anti-PSMA monoclonal antibody J591 from a phase II study by Tawaga and colleagues support the continued clinical and preclinical development of radioimmunotherapy for solid tumors.

MeSH terms

Antibodies, Monoclonal / therapeutic use*
Antigens, Surface / immunology
Antineoplastic Agents / therapeutic use*
Clinical Trials, Phase II as Topic
Glutamate Carboxypeptidase II / antagonists & inhibitors
Glutamate Carboxypeptidase II / immunology
Humans
Male
Prostatic Neoplasms / immunology
Prostatic Neoplasms / radiotherapy*
Radioimmunotherapy*

Substances

Antibodies, Monoclonal
Antigens, Surface
Antineoplastic Agents
J591 monoclonal antibody
FOLH1 protein, human
Glutamate Carboxypeptidase II